Compare Ascendis Pharma A/S (ASND) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Charles River Laboratories Intl. Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Charles River Laboratories Intl. Inc trades at $233.41 (market cap $11.24B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap. Which is the better fit depends on your goals.
| ASND | CRL | |
|---|---|---|
Market Cap | $17.74B | $11.24B |
Sector | Health | Health |
52-Week High | $277.18 | $233.60 |
52-Week Low | $163.32 | $145.57 |
Enterprise Value | $18.11B | $14.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Charles River Laboratories (CRL) trades at $233.41, down slightly by 0.08% today, with a bullish technical signal supported by moving averages. The company shows strong operational cash flow of $737.65M for 2025 but faces profitability challenges with negative net income margin of -4.59% and ROE of -6.02%. Recent earnings have consistently beaten expectations, and analyst consensus remains strongly positive with 72% buy ratings.
CRL presents a mixed investment case: strong cash generation and strategic collaborations like the Lilly TuneLab partnership provide growth catalysts, but negative profitability metrics and high valuation ratios (P/E 684.85) pose risks. The stock's outlook depends on margin improvement and successful execution of recent business initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
